A5332: Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)

Study Location:

BaltimoreIndia

Topic:

Cardiovascular Disease and HIV

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT02344290?term=a5332&rank=1

IRB#:

Pro00011068

Coordinator:

Anna Wimpelberg (Washington)

Ilene Wiggins, RN (Baltimore)

Nishi Suryavanshi (India)

Enrollment:

Closed

Trial Period:

Ongoing

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months. The trial is testing the effect of statin therapy on preventing heart disease and death in HIV-infected persons on HIV medications who do not meet guidelines for starting statins.       

  • HIV infected men and women between the ages of 40 and 75
  • On HIV medications for at least 6 months
  • CD4 cell count greater than 100
  • No history of cardiovascular disease, such as heart attack, stroke, etc.
  • No history of cancer in the last 3 years
  • Not currently using a statin drug

Anna Wimpelberg (Washington)
202-797-3589
awimpelberg@whitman-walker.org


​Ilene Wiggins, RN (Baltimore)
410-614-2766
iwiggin1@jhmi.edu

Categories

Location
Topic

Clinical Trials

P2001 (DAIDS ID 12026): Evaluating the Pharmacokinetics,...

TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at...

Read More

A5290, A Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More

P1060:  Phase II, parallel, randomized, clinical trials...

A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

HPTN 069: A Phase II Randomized, Double-Blind, Study of the...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

Read More